Home > Boards > US OTC > Medical - Equipment > Positron Corporation (POSC)

March 24, 2020 Dear Positron Shareholders, On behalf of our

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Jackers1 Member Profile
Followed By 0
Posts 8
Boards Moderated 0
Alias Born 10/24/19
160x600 placeholder
Jackers1   Thursday, 04/30/20 02:06:27 PM
Re: Medtrade77 post# 19398
Post # of 19426 
March 24, 2020
Dear Positron Shareholders,
On behalf of our investors and supporters we are pleased to offer some forward guidance to our business.
The cardiac PET industry is healthy and in the best position we have seen in a decade. A great deal of the industry’s vision and best practices come from the leadership of the societies and coalitions within the industry fighting to solidify reimbursement and the advocacy of this superior cardiac diagnostic technology. We are confident there will be continued support and advancements the modality. Additionally we are encouraged by the supply of radiopharmaceuticals, new and improved coronary flow reserve software complementing our Attrius® PET scanner and an overall evolution underway from SPECT to PET, which all play an important role in the increase in demand for PET. Positron is well positioned to deliver systems from inventory and through its joint venture partner Neusoft Medical.
Over the past year we have increased revenues generated from annual clinical and technical services agreements while also improving margins. We are pleased with our sales pipeline which we expect to report new developments in the near future.
As a company we continue to maintain our focus on our systems, services and facilitating customer’s needs towards successful cardiac PET programs. We are in the process of divesting of all SPECT assets as well as perfecting value and income from royalty agreements; all with the intent of improving our balance sheet with capital that will be applied to expanding operations and customer acquisitions.
Positron is also committed to meeting the requirements of a public company. We are exploring the timing to return to a fully reporting company and will begin enacting corporate governance required. We believe this is a key component for growth and investor confidence.
In recent years there have been a number of hurdles that both Positron and the cardiac PET industry have overcome; all of which only made us stronger and in the best position to lead this industry with our PET technology and services. Positron offers the best in PET through quality, services, price and the only dedicated PET system in the world.
In coming months it is our plan to report our progress on PET system sales, industry growth, capital and income from non-PET properties, additional personnel and initiatives on expansion and the return to a fully reporting public company.
As always thank you for your support of Positron. We will update any and all material developments in real time. Best Regards,
Adel Abdullah Positron Corporation President

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences